Physician profile
Sally J Bailey
NPI 1700815677
$343,567.69
in general payments reported to CMS, 2019-2025
25 companies · $95K in 2025
The $95K reported for 2025 was more than what 98% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $25K · 2021: $27K · 2022: $37K · 2023: $57K · 2024: $83K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $154K · Travel and Lodging: $32K · Consulting Fee: $29K · Food and Beverage: $13K · Honoraria: $6,963 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $154,005.10 |
| Travel and Lodging | $32,489.98 |
| Consulting Fee | $28,641.20 |
| Food and Beverage | $13,006.56 |
| Honoraria | $6,963.00 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $97,769.07 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $83,776.02 | 2019-2025 | Dupixent |
| Genzyme Corporation | $66,118.05 | 2019-2025 | |
| Alk-Abello, INC | $45,530.01 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Glaxosmithkline, LLC. | $19,373.46 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $15,035.11 | 2023-2025 | Xolair |
| Kaleo, INC. | $4,831.28 | 2019-2025 | Auvi-Q |
| Grifols USA, LLC | $2,897.40 | 2024-2025 | Xembify |
| Abbvie INC. | $2,890.93 | 2023-2024 | Rinvoq |
| Blueprint Medicines Corporation | $2,306.38 | 2023-2024 | Ayvakit |
| Pfizer INC. | $615.11 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $526.61 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Biocryst US Sales Co., LLC | $517.31 | 2022-2023 | Orladeyo |
| Greer Laboratories, INC. | $299.97 | 2025 | Oralair, Palforzia |
| Genentech USA, INC. | $240.86 | 2019-2025 | Xolair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $218.60 | 2023-2024 | Vtama |
| Incyte Corporation | $97.38 | 2022-2025 | Opzelura |
| Amgen INC. | $96.16 | 2021-2025 | Tezspire |
| Adma Biomanufacturing LLC | $90.45 | 2023 | |
| Aimmune Therapeutics, INC. | $88.31 | 2021-2022 | |
| Csl Behring | $81.21 | 2024 | Haegarda |
| Sanofi US Services INC. | $55.25 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.22 | 2023-2024 | Cuvitru, Takhzyro |
| Teva Pharmaceuticals USA, INC. | $36.49 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.